Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.
Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity, and many patients continue to experience symptoms despite optimal therapy. As one of the world’s largest and most experienced COPD research programs, the Temple Lung Center offers access to clinical trials evaluating new pharmacologic, device-based, and comprehensive treatment approaches.
HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.
A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.